{"id":44301,"date":"2025-10-24T23:08:56","date_gmt":"2025-10-24T15:08:56","guid":{"rendered":"https:\/\/flcube.com\/?p=44301"},"modified":"2025-10-24T23:08:57","modified_gmt":"2025-10-24T15:08:57","slug":"sanofi-q3-2025-results-7-revenue-growth-dupixent-drives-pharma-upswing","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44301","title":{"rendered":"Sanofi Q3\u202f2025 Results: 7\u202f% Revenue Growth, Dupixent Drives Pharma Upswing"},"content":{"rendered":"\n<p>Sanofi (<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ: SNY<\/a>) today reported its third\u2011quarter 2025 financial performance, posting a <strong>7\u202f% year\u2011on\u2011year increase in global revenues in constant\u2011currency terms to \u20ac12.43\u202fbillion ($14.43\u202fbillion).<\/strong> Over the first nine months of the year, sales climbed <strong>8.7\u202f% YOY to \u20ac32.32\u202fbillion ($37.5\u202fbillion).<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-highlights\"><strong>Financial Highlights<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q3\u202f2025<\/th><th>YoY %<\/th><th>1\u20119\u202fM 2025<\/th><th>YoY %<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Revenue<\/strong><\/td><td>\u20ac12.43\u202fbn<\/td><td>+7.0\u202f%<\/td><td>\u2013<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Total Sales<\/strong><\/td><td>\u20ac12.43\u202fbn<\/td><td>+7.0\u202f%<\/td><td>\u20ac32.32\u202fbn<\/td><td>+8.7\u202f%<\/td><\/tr><tr><td><strong>Pharma Sales<\/strong><\/td><td>\u20ac?\u202fbn<\/td><td>+?\u202f%<\/td><td>\u20ac?\u202fbn<\/td><td>+?\u202f%<\/td><\/tr><tr><td><strong>Vaccine Sales<\/strong><\/td><td>\u20ac3.80\u202fbn<\/td><td>\u20137.8\u202f%<\/td><td>\u2013<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Other Medicines<\/strong><\/td><td>\u20ac3.80\u202fbn<\/td><td>\u20133.8\u202f%<\/td><td>\u2013<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><em>Key drivers: 40.8\u202f% sales growth in newly launched medicines and vaccines; 26.2\u202f% expansion for allergy drug <strong>Dupixent<\/strong> (dupilumab), which surpassed \u20ac4\u202fbn in quarterly global sales for the first time.<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-dupixent-amp-pharma-momentum\"><strong>Dupixent &amp; Pharma Momentum<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dupixent sales<\/strong> reached <strong>\u20ac4.20\u202fbn ($4.90\u202fbn)<\/strong>, breaking both the \u20ac4\u202fbn quarterly global sales threshold and the \u20ac3\u202fbn U.S. mark.<\/li>\n\n\n\n<li><strong>Pharma launches<\/strong> grew <strong>57.1\u202f%<\/strong> to <strong>\u20ac1.00\u202fbn ($1.20\u202fbn)<\/strong>, driven by hemophilia drug <strong>ALTUVIIIO<\/strong> (rFVIII) and RSV vaccine <strong>Beyfortus<\/strong>.<\/li>\n\n\n\n<li>The vaccine business declined <strong>7.8\u202f%<\/strong> to \u20ac3.80\u202fbn, offset by Dupixent\u2019s robust performance.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-geographic-performance\"><strong>Geographic Performance<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Q3\u202f2025 Sales (\u20ac\u202fmln)<\/th><th>YoY %<\/th><th>1\u20119\u202fM Sales (\u20ac\u202fmln)<\/th><th>YoY %<\/th><\/tr><\/thead><tbody><tr><td><strong>United States<\/strong><\/td><td>6,838<\/td><td>+11.1\u202f%<\/td><td>16,373<\/td><td>+14.1\u202f%<\/td><\/tr><tr><td><strong>Europe<\/strong><\/td><td>2,589<\/td><td>+2.8\u202f%<\/td><td>6,733<\/td><td>+2.2\u202f%<\/td><\/tr><tr><td><strong>Rest of World<\/strong><\/td><td>3,007<\/td><td>+1.9\u202f%<\/td><td>9,217<\/td><td>+4.9\u202f%<\/td><\/tr><tr><td><strong>China<\/strong><\/td><td>689<\/td><td>+2.7\u202f%<\/td><td>2,077<\/td><td>+0.9\u202f%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><em>China\u2019s modest 2.7\u202f% growth occurred amid a \u201cslightly declining market\u201d influenced by the renewed national reimbursement drug list and volume\u2011based procurement.<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestones\"><strong>Regulatory Milestones<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China:<\/strong> FDA\u2011like approval of CD3\u2011targeted antibody <strong>Tzield<\/strong> (teplizumab) to delay progression of Type\u202f1 diabetes.<\/li>\n\n\n\n<li><strong>U.S.:<\/strong> Global approval of Bruton\u2019s tyrosine kinase inhibitor <strong>Wayrilz<\/strong> (rilzabrutinib) for immune thrombocytopenia; a major launch with potential across rare diseases.<\/li>\n\n\n\n<li><strong>Q3\u202f2025:<\/strong> Eight new approval filings; six additional regulatory decisions expected in Q4\u202f2025.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-outlook\"><strong>Outlook<\/strong><\/h2>\n\n\n\n<p>Sanofi\u2019s Q3 results underscore the strength of its newly launched portfolio and the flagship Dupixent. The company remains focused on expanding its rare\u2011disease pipeline and capturing growth in high\u2011margin specialty markets while navigating competitive vaccine dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025-10-24-05-30-00-3172594-en.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025-10-24-05-30-00-3172594-en.\"><\/object><a id=\"wp-block-file--media-cc3b1b9d-70e6-46ac-a9e1-4804501d61af\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025-10-24-05-30-00-3172594-en.pdf\">2025-10-24-05-30-00-3172594-en<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025-10-24-05-30-00-3172594-en.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-cc3b1b9d-70e6-46ac-a9e1-4804501d61af\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi (NASDAQ: SNY) today reported its third\u2011quarter 2025 financial performance, posting a 7\u202f% year\u2011on\u2011year increase&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44303,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[27,867,147],"class_list":["post-44301","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-finanical-reports","tag-nasdaq-sny","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanofi Q3\u202f2025 Results: 7\u202f% Revenue Growth, Dupixent Drives Pharma Upswing - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sanofi (NASDAQ: SNY) today reported its third\u2011quarter 2025 financial performance, posting a 7\u202f% year\u2011on\u2011year increase in global revenues in constant\u2011currency terms to \u20ac12.43\u202fbillion ($14.43\u202fbillion). Over the first nine months of the year, sales climbed 8.7\u202f% YOY to \u20ac32.32\u202fbillion ($37.5\u202fbillion).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44301\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi Q3\u202f2025 Results: 7\u202f% Revenue Growth, Dupixent Drives Pharma Upswing\" \/>\n<meta property=\"og:description\" content=\"Sanofi (NASDAQ: SNY) today reported its third\u2011quarter 2025 financial performance, posting a 7\u202f% year\u2011on\u2011year increase in global revenues in constant\u2011currency terms to \u20ac12.43\u202fbillion ($14.43\u202fbillion). Over the first nine months of the year, sales climbed 8.7\u202f% YOY to \u20ac32.32\u202fbillion ($37.5\u202fbillion).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44301\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-24T15:08:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-24T15:08:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2405.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44301#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44301\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi Q3\u202f2025 Results: 7\u202f% Revenue Growth, Dupixent Drives Pharma Upswing\",\"datePublished\":\"2025-10-24T15:08:56+00:00\",\"dateModified\":\"2025-10-24T15:08:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44301\"},\"wordCount\":296,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44301#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2405.webp\",\"keywords\":[\"Finanical Reports\",\"NASDAQ: SNY\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44301#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44301\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44301\",\"name\":\"Sanofi Q3\u202f2025 Results: 7\u202f% Revenue Growth, Dupixent Drives Pharma Upswing - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44301#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44301#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2405.webp\",\"datePublished\":\"2025-10-24T15:08:56+00:00\",\"dateModified\":\"2025-10-24T15:08:57+00:00\",\"description\":\"Sanofi (NASDAQ: SNY) today reported its third\u2011quarter 2025 financial performance, posting a 7\u202f% year\u2011on\u2011year increase in global revenues in constant\u2011currency terms to \u20ac12.43\u202fbillion ($14.43\u202fbillion). Over the first nine months of the year, sales climbed 8.7\u202f% YOY to \u20ac32.32\u202fbillion ($37.5\u202fbillion).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44301#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44301\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44301#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2405.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2405.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sanofi Q3\u202f2025 Results: 7\u202f% Revenue Growth, Dupixent Drives Pharma Upswing\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44301#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi Q3\u202f2025 Results: 7\u202f% Revenue Growth, Dupixent Drives Pharma Upswing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi Q3\u202f2025 Results: 7\u202f% Revenue Growth, Dupixent Drives Pharma Upswing - Insight, China&#039;s Pharmaceutical Industry","description":"Sanofi (NASDAQ: SNY) today reported its third\u2011quarter 2025 financial performance, posting a 7\u202f% year\u2011on\u2011year increase in global revenues in constant\u2011currency terms to \u20ac12.43\u202fbillion ($14.43\u202fbillion). Over the first nine months of the year, sales climbed 8.7\u202f% YOY to \u20ac32.32\u202fbillion ($37.5\u202fbillion).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44301","og_locale":"en_US","og_type":"article","og_title":"Sanofi Q3\u202f2025 Results: 7\u202f% Revenue Growth, Dupixent Drives Pharma Upswing","og_description":"Sanofi (NASDAQ: SNY) today reported its third\u2011quarter 2025 financial performance, posting a 7\u202f% year\u2011on\u2011year increase in global revenues in constant\u2011currency terms to \u20ac12.43\u202fbillion ($14.43\u202fbillion). Over the first nine months of the year, sales climbed 8.7\u202f% YOY to \u20ac32.32\u202fbillion ($37.5\u202fbillion).","og_url":"https:\/\/flcube.com\/?p=44301","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-24T15:08:56+00:00","article_modified_time":"2025-10-24T15:08:57+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2405.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44301#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44301"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi Q3\u202f2025 Results: 7\u202f% Revenue Growth, Dupixent Drives Pharma Upswing","datePublished":"2025-10-24T15:08:56+00:00","dateModified":"2025-10-24T15:08:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44301"},"wordCount":296,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44301#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2405.webp","keywords":["Finanical Reports","NASDAQ: SNY","Sanofi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44301#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44301","url":"https:\/\/flcube.com\/?p=44301","name":"Sanofi Q3\u202f2025 Results: 7\u202f% Revenue Growth, Dupixent Drives Pharma Upswing - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44301#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44301#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2405.webp","datePublished":"2025-10-24T15:08:56+00:00","dateModified":"2025-10-24T15:08:57+00:00","description":"Sanofi (NASDAQ: SNY) today reported its third\u2011quarter 2025 financial performance, posting a 7\u202f% year\u2011on\u2011year increase in global revenues in constant\u2011currency terms to \u20ac12.43\u202fbillion ($14.43\u202fbillion). Over the first nine months of the year, sales climbed 8.7\u202f% YOY to \u20ac32.32\u202fbillion ($37.5\u202fbillion).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44301#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44301"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44301#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2405.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2405.webp","width":1080,"height":608,"caption":"Sanofi Q3\u202f2025 Results: 7\u202f% Revenue Growth, Dupixent Drives Pharma Upswing"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44301#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi Q3\u202f2025 Results: 7\u202f% Revenue Growth, Dupixent Drives Pharma Upswing"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2405.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44301"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44301\/revisions"}],"predecessor-version":[{"id":44304,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44301\/revisions\/44304"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44303"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44301"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44301"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}